Reuters logo
REFILE-BRIEF-Astex Pharmaceuticals responds to further misleading claims made by Sarissa Capital
October 10, 2013 / 2:49 AM / 4 years ago

REFILE-BRIEF-Astex Pharmaceuticals responds to further misleading claims made by Sarissa Capital

Oct 9 (Reuters) - Astex Pharmaceuticals Inc : * Says disappointed that Sarissa Capital continues to mislead Astex

stockholders with information that is incomplete * Says $8.50 per share all-cash transaction with Otsuka was in the best

interests of all Astex stockholders * Says no third parties have approached Astex with an interest to acquire the

company * Source text for Eikon * Further company coverage

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below